Quality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study

2015 ◽  
Vol 24 (2) ◽  
pp. 667-674 ◽  
Author(s):  
Beate Mayrbäurl ◽  
Johannes M. Giesinger ◽  
Sonja Burgstaller ◽  
Gudrun Piringer ◽  
Bernhard Holzner ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Observational Study ◽  
Advanced Colorectal Cancer ◽  
Single Center ◽  
Single Center Observational Study

A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis

Immunotherapy ◽  
2021 ◽  
Author(s):  
Victor Hémar ◽  
Etienne Rivière ◽  
Carine Greib ◽  
Irène Machelart ◽  
Manon Roucoules ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Observational Study ◽  
Replacement Therapy ◽  
Risk Of Infection ◽  
Single Center ◽  
Secondary Immunodeficiency ◽  
Immunoglobulin Replacement Therapy ◽  
Immunoglobulin Replacement ◽  
Single Center Observational Study

Aim: To describe the effects of a summertime pause (SP) in immunoglobulin replacement therapy (IgRT). Patients & methods: We conducted a prospective single-center observational study, including 44 patients undergoing intravenous IgRT between May and June 2019 in a French teaching hospital. Results: IgRT was interrupted in 23 patients from June to October. Patients who underwent an SP were older, more likely to have secondary immunodeficiency (SID) and received lower doses of immunoglobulin and more antibiotics during winter. Most patients who did not undergo an SP had severe primary immunodeficiency. The SP did not increase the risk of infection, improved the quality of life and reduced treatment costs. Conclusion: SP in IgRT is a safe practice and should be considered for patients with mild SID.

Health related quality of life in older or frail patients with advanced colorectal cancer treated with dose reduced capecitabine

2018 ◽  
Vol 9 (6) ◽  
pp. 659-664 ◽  
Author(s):  
Daniel Breadner ◽  
Mark David Vincent ◽  
Derek Jonker ◽  
Christine Cripps ◽  
Paul Klimo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Advanced Colorectal Cancer ◽  
Health Related Quality ◽  
Frail Patients ◽  
Related Quality ◽  
Health Related

Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.

1995 ◽  
Vol 13 (9) ◽  
pp. 2317-2323 ◽  
Author(s):  
M Hill ◽  
A Norman ◽  
D Cunningham ◽  
M Findlay ◽  
M Watson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Advanced Colorectal Cancer ◽  
Symptomatic Improvement ◽  
Interferon Alfa ◽  
Life Questionnaire ◽  
European Organization ◽  
Significant Difference ◽  
Venous Infusion

PURPOSE The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer. PATIENTS AND METHODS Patients who attended our unit with histologically confirmed advanced colorectal cancer were randomized to receive either PVI 5-FU 300 mg/m2/d via Hickman line, and IFN 5 MU subcutaneously three times weekly, or PVI 5-FU alone. Treatment was given for a maximum of two 10-week blocks, with a 2-week gap for reassessment of all parameters. Quality of life (QL) was measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) pretreatment and every 6 weeks thereafter. RESULTS A total of 160 patients were randomized, with 155 eligible for assessment. Radiologic response was observed in 43 patients (28%): 17 of 77 (22%) in the 5-FU-plus-IFN arm (all partial responses [PRs]) and 26 of 78 (33%) in the 5-FU-alone group (complete responses [CRs] and 22 PRs) (difference not significant). Symptomatic improvement occurred in the majority of patients, and equally in both arms: 61% to 80% depending on the symptom. There was no significant difference between the two groups in failure-free survival (median, 161 v 193 days) or overall survival (median, 328 v 357 days). However, patients who received IFN did experience significantly more toxicity in the form of leukopenia (P = .001), neutropenia (P = .04), mucositis (P = .008), and alopecia (P = .0002). There were no toxic deaths and few notable differences in QL between the two arms. CONCLUSION This study confirms that PVI 5-FU is effective in treating the symptoms associated with metastatic colorectal carcinoma, with only mild to moderate toxicity and maintenance of QL. IFN 5 MU three times weekly does not enhance these palliative benefits.

scholarly journals How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials

2017 ◽  
Vol 28 (9) ◽  
pp. 2077-2085 ◽  
Author(s):  
F. Bonnetain ◽  
C. Borg ◽  
R.R. Adams ◽  
J.A. Ajani ◽  
A. Benson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Advanced Colorectal Cancer ◽  
Life Assessment ◽  
Cancer Clinical Trials ◽  
Health Related Quality ◽  
Quality Of Life Assessment ◽  
Related Quality ◽  
Health Related

A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor—Resistant Advanced Colorectal Cancer

2004 ◽  
Vol 22 (15) ◽  
pp. 3023-3031 ◽  
Author(s):  
Rohit Lal ◽  
James Dickson ◽  
David Cunningham ◽  
Ian Chau ◽  
Andrew R. Norman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Disease Progression ◽  
Advanced Colorectal Cancer ◽  
Phase Iii ◽  
Random Assignment ◽  
Duration Of Disease ◽  
Grade 3 ◽  
Synthase Inhibitor

Purpose Irinotecan given until disease progression is an accepted standard treatment for advanced colorectal cancer (CRC) resistant to fluoropyrimidines. It is not known whether a predefined period of irinotecan treatment would result in similar duration of disease control. We performed a multicenter phase III trial to compare the two policies of defined-duration versus continuous irinotecan treatment. Patients and Methods Three hundred thirty-three eligible patients with advanced CRC progressing on or within 24 weeks of completing fluoropyrimidine-based chemotherapy were prospectively registered. After receiving eight cycles of irinotecan given at 350 mg/m2 once every 3 weeks, 55 patients with responding or stable disease were randomly assigned to stop irinotecan (n = 30) or continue until disease progression (n = 25). Registered patients were not randomly assigned predominantly due to disease progression (n = 236) and intolerable toxicity (n = 38). Results From the time of random assignment, there were no differences in failure-free survival (P = .999) or overall survival (P = .11) between the two arms. No difference was seen in mean global health status quality-of-life score between the two arms at 12 weeks after random assignment. No grade 3 diarrhea and febrile neutropenia was seen in the continue-irinotecan arm after random assignment. Conclusion For most patients, the decision to continue on irinotecan beyond 24 weeks is influenced by disease progression or treatment-related toxicity. However, for 17% of patients in whom this decision is clinically relevant, there seems to be little benefit from continuing irinotecan, though the drug was well tolerated without any deterioration in quality of life.

scholarly journals Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer

Cancer ◽  
1994 ◽  
Vol 73 (3) ◽  
pp. 556-562 ◽  
Author(s):  
Bengt Glimelius ◽  
Katarina Hoffman ◽  
Wilhelm Graf ◽  
Lars Påhlman ◽  
Per-Olow Sjödén ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Advanced Colorectal Cancer
Sign in / Sign up

Export Citation Format

Share Document